Sigma-1 receptor modulators and molecular chaperone therapies represent two complementary approaches to neuroprotection in Alzheimer's disease. The sigma-1 receptor (SIGMAR1) is a chaperone protein located in the endoplasmic reticulum that plays critical roles in ER stress response, calcium homeostasis, mitochondrial function, and anti-apoptotic signaling [1]. Molecular chaperones, including heat shock proteins (HSPs), assist in proper protein folding and help prevent the aggregation of pathological proteins like amyloid-beta and tau [2].
These approaches address a fundamental limitation of amyloid-targeting therapies — even after clearing amyloid plaques, downstream neurodegeneration continues. Sigma-1 receptor agonism and molecular chaperone therapy provide neuroprotection through pleiotropic mechanisms that preserve neuronal health and function, potentially modifying disease progression rather than merely removing pathological proteins.
Anavex Life Sciences (NASDAQ: AVXL) is a clinical-stage pharmaceutical company headquartered in New York, developing novel drug candidates targeting sigma-1 receptors and muscarinic receptors for the treatment of Alzheimer's disease and Parkinson's disease.
Blarcamesine operates through sigma-1 receptor activation to reduce ER stress, normalize calcium homeostasis, and provide anti-apoptotic neuroprotection. The dual mechanism of sigma-1 agonism and muscarinic activation provides broad neuroprotective effects.
Axsome Therapeutics (NASDAQ: AXSM) is a clinical-stage biopharmaceutical company developing novel therapies for central nervous system disorders, including Alzheimer's disease.
AXS-060 targets sigma-1 receptors highly expressed in brain regions involved in cognition and emotion, including the hippocampus and prefrontal cortex. The drug addresses neuropsychiatric symptoms of Alzheimer's disease while providing neuroprotective effects through sigma-1 receptor activation.
Annovis Bio (NYSE: ANVS) is a clinical-stage drug platform company developing therapies for Alzheimer's disease, Parkinson's disease, and other neurodegenerative conditions.
Bunodimod's dual mechanism provides neuroprotection through sigma-1 receptor agonism while also inhibiting mTOR signaling to enhance autophagy and protein clearance. This combination addresses both neuroprotection and protein homeostasis.
Prilenia is a clinical-stage biotechnology company developing therapeutics for neurodegenerative and neurodevelopmental disorders.
Pridopidine has demonstrated neuroprotective effects through sigma-1 receptor activation in preclinical models. While primarily developed for Huntington's disease and ALS, the sigma-1 agonist mechanism is relevant to Alzheimer's disease therapeutic development.
Fujifilm Holdings Corporation (TSE: 4901) is a Japanese multinational conglomerate with significant pharmaceutical development capabilities.
T-817MA is a small molecule sigma-1 receptor agonist that has shown neuroprotective effects in preclinical models of Alzheimer's disease. The compound promotes neuronal survival under ER stress conditions and improves mitochondrial function.
Relmada Therapeutics (NASDAQ: RLMD) is a clinical-stage pharmaceutical company developing novel therapies for central nervous system disorders.
Relmada's sigma-1 receptor program focuses on developing oral small molecules that provide neuroprotection through sigma-1 receptor-mediated pathways. The approach addresses multiple aspects of neurodegeneration simultaneously.
Gain Therapeutics (NASDAQ: GANX) is a clinical-stage biotechnology company developing small molecule therapeutic chaperones for neurodegenerative diseases and lysosomal storage disorders.
While primarily focused on Parkinson's disease, Gain's therapeutic chaperone approach is directly relevant to Alzheimer's disease. The company's SEE-Tx platform identifies small molecules that stabilize misfolded proteins, a mechanism applicable to multiple neurodegenerative diseases.
Cognition Therapeutics is a clinical-stage pharmaceutical company developing small molecule therapeutics targeting sigma-2 receptors for Alzheimer's disease and other protein aggregation disorders.
CT-1812 targets sigma-2 receptors involved in cellular stress response and cholesterol homeostasis. The compound protects synaptic integrity by displacing toxic oligomers from synaptic membranes, providing a complementary mechanism to sigma-1 agonists.
Neurotrope Bioscience focused on developing protein kinase C (PKC) activators for neurological conditions, including Alzheimer's disease.
Bryostatin promotes synaptogenesis, enhances long-term potentiation (LTP), and protects against excitotoxicity. The mechanism involves upregulation of synaptic proteins including synapsin I and PSD-95, providing a distinct approach to synaptic repair and neuroprotection.
Several companies are developing Hsp90 and Hsp70 modulators as molecular chaperone therapies:
| Company | Candidate | Mechanism | Indication | Stage |
|---|---|---|---|---|
| Anavex Life Sciences | Blarcamesine | Sigma-1 agonist | AD | Phase 2/3 |
| Axsome Therapeutics | AXS-060 | Sigma-1 agonist | AD agitation | Phase 2/3 |
| Annovis Bio | Bunodimod | Sigma-1 agonist + mTOR inhibitor | AD, PD | Phase 2/3 |
| Fujifilm | T-817MA | Sigma-1 agonist | AD, PD | Phase 2 |
| Prilenia | Pridopidine | Sigma-1 agonist | HD, ALS | Phase 2 |
| Relmada | Research program | Sigma-1 agonist | CNS disorders | Preclinical |
| Gain Therapeutics | GT-02287 | GCase chaperone | GBA-PD | Phase 1b |
| Cognition Therapeutics | CT-1812 | Sigma-2 modulator | AD | Phase 1-2 |
| Neurotrope | Bryostatin-1 | PKC activator | AD | Phase 2 |
The sigma-1 receptor operates through pleiotropic mechanisms that address multiple aspects of neurodegeneration simultaneously [4]:
This multi-target approach is particularly attractive for Alzheimer's disease, where multiple pathological processes contribute to neurodegeneration.
Molecular chaperone therapy aims to:
The chaperone system (Hsp70, Hsp90, Hsp40, cochaperones) represents an endogenous protein homeostasis network that can be pharmacologically enhanced.